Virtus Investment Advisers LLC Has $1.67 Million Stock Holdings in Insulet Corporation $PODD

Virtus Investment Advisers LLC lifted its position in Insulet Corporation (NASDAQ:PODD) by 3.2% during the 2nd quarter, Holdings Channel reports. The firm owned 5,316 shares of the medical instruments supplier’s stock after buying an additional 167 shares during the quarter. Virtus Investment Advisers LLC’s holdings in Insulet were worth $1,670,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. Marshall Financial Group LLC acquired a new stake in shares of Insulet during the second quarter worth approximately $943,000. Inspire Investing LLC increased its holdings in Insulet by 299.5% during the 1st quarter. Inspire Investing LLC now owns 4,119 shares of the medical instruments supplier’s stock valued at $1,082,000 after purchasing an additional 3,088 shares in the last quarter. Illinois Municipal Retirement Fund raised its position in Insulet by 41.3% in the 2nd quarter. Illinois Municipal Retirement Fund now owns 12,030 shares of the medical instruments supplier’s stock valued at $3,780,000 after purchasing an additional 3,514 shares during the last quarter. Gradient Investments LLC acquired a new position in Insulet in the second quarter worth $17,429,000. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Insulet by 1.9% during the first quarter. Goldman Sachs Group Inc. now owns 579,302 shares of the medical instruments supplier’s stock worth $152,130,000 after purchasing an additional 10,628 shares during the last quarter.

Insulet Price Performance

Shares of PODD stock opened at $326.80 on Friday. The firm’s 50 day moving average price is $322.06 and its two-hundred day moving average price is $316.28. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. Insulet Corporation has a 52-week low of $230.05 and a 52-week high of $354.88. The stock has a market cap of $22.99 billion, a PE ratio of 99.33, a PEG ratio of 2.64 and a beta of 1.39.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company had revenue of $521.70 million for the quarter, compared to the consensus estimate of $678.70 million. During the same quarter in the prior year, the business posted $1.08 EPS. The firm’s quarterly revenue was up 29.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.

Insider Transactions at Insulet

In related news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the transaction, the senior vice president owned 3,890 shares of the company’s stock, valued at $1,356,870.90. This trade represents a 17.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Prem Singh sold 687 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares of the company’s stock, valued at $1,200,925.44. The trade was a 16.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.39% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts recently issued reports on PODD shares. Wall Street Zen upgraded shares of Insulet from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Sanford C. Bernstein reissued an “outperform” rating on shares of Insulet in a research note on Friday, November 21st. Canaccord Genuity Group set a $432.00 price target on shares of Insulet in a report on Monday. Zacks Research raised Insulet from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 14th. Finally, Wolfe Research increased their price objective on Insulet from $350.00 to $375.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Insulet presently has an average rating of “Moderate Buy” and an average price target of $379.65.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.